Mitazalimab Biosimilar - Research Grade

Human

CD40

>1mg/ml

IgG1 - lambda2

CHO Cells

Anti-Mouse CD40 (FGK4.5) In Vivo Antibody - Low Endotoxin (ICH1073), Bulk Anti-Human CD40 (G28.5) Antibody (ICH1156), Dacetuzumab Biosimilar - Research Grade (ICH5030), Sotigalimab Biosimilar - Research Grade (ICH5031), Selicrelumab Biosimilar - Research Grade (ICH5032), Lucatumumab Biosimilar - Research Grade (ICH5129), Abiprubart Biosimilar - Research Grade (ICH5323), Bleselumab Biosimilar - Research Grade (ICH5407), Cifurtilimab Biosimilar - Research Grade (ICH5437), Dalnicastobart Biosimilar - Research Grade (ICH5462), Giloralimab Biosimilar - Research Grade (ICH5571), Iscalimab Biosimilar - Research Grade (ICH5610), Ravagalimab Biosimilar - Research Grade (ICH5806), Teneliximab Biosimilar - Research Grade (ICH5915)

https://www.imgt.org/mAb-DB/

ICH3002

P25942

Blue ice

This product is a research-grade, unconjugated recombinant analog of mitazalimab, an agonistic antibody directed against human CD40. It is a non-therapeutic biosimilar intended strictly for research use, not for human or veterinary application. Supplied unconjugated as an intact human IgG1 (lambda light chain) format, it reproduces the CD40-directed binding specificity of the originator molecule and is useful as a well-defined tool for probing CD40 biology and CD40-agonist pharmacology in the laboratory. Typical applications include use as a binding and functional reference standard, a positive or benchmarking control in receptor-engagement and agonism assays, an isotype-matched comparator in antibody-characterization workflows, and a reagent for in-vitro assay development. Because it is offered at research grade, it is available in bulk milligram-to-gram quantities and in low-endotoxin preparations (research grade <1 EU/mg; ultra-low <0.5 EU/mg) suitable for sensitive cell-based and preclinical model work. It carries no therapeutic formulation claims and is provided for functional and biochemical characterization only. CD40 (TNFRSF5; UniProt P25942) is a type I transmembrane costimulatory receptor of the TNF receptor superfamily. It is expressed on antigen-presenting cells including dendritic cells, B lymphocytes, macrophages and monocytes, and also on some endothelial and epithelial cells and various tumors. Its natural ligand is CD40L (CD154), expressed largely on activated CD4+ T cells and platelets. Ligation triggers receptor clustering and recruitment of TRAF adaptor proteins, activating NF-kB, MAPK and other pathways. In B cells this drives proliferation, germinal-center formation, immunoglobulin class-switch recombination and affinity maturation; in dendritic cells and macrophages it promotes maturation, upregulation of costimulatory molecules, and pro-inflammatory cytokine secretion. Because CD40 engagement can license antigen-presenting cells and prime cytotoxic T-cell responses, agonistic CD40 antibodies are studied as immune-activating agents in oncology, contrasting with CD40/CD40L-blocking approaches explored in autoimmunity and transplantation.

CD40, Bp50, CDW40, TNFRSF5, p50, CD40 (protein), CD40 molecule

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks